Engineered Type III-E CRISPR Effectors for Precise Nucleic Acid Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome and epigenome manipulation technologies are limited in scale, efficacy, and ease of use, hindering the development of applications in biotechnology and human therapeutics, and existing CRISPR-Cas systems lack diversity in mechanisms for programmable nucleic acid manipulation.
Innovation Solution
Development of non-naturally occurring Type III-E CRISPR-Cas systems with engineered RNA guides and effector proteins, capable of targeting and modifying nucleic acids, including cleavage, insertion, and deletion events, and methods for computational identification and experimental validation of these systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing CRISPR-Cas systems are used for genome manipulation, then nucleic acid targeting capability is achieved, but diversity in manipulation mechanisms is limited
Solution Approach 1:
The patent segments the CRISPR system into distinct functional modules: Type III-E CRISPR-Cas effector proteins with specific domains (DEAL, RAMP, CHAT), guide RNAs with structured regions, and modular domain combinations. This segmentation enables mixing and matching of domains to create diverse effector proteins with different nucleic acid manipulation capabilities (cleavage, insertion, deletion, base editing) while maintaining a common architectural framework.
Solution Approach 2:
The patent creates universal effector protein platforms where Type III-E CRISPR-Cas proteins can perform multiple functions through domain combinations and guide RNA variations. The same effector protein architecture can be configured for DNA cleavage, RNA cleavage, base editing, or insertion/deletion events by changing domains or guide sequences, providing multi-functionality without requiring entirely different system designs.
2Productivity
If genome manipulation scale is increased, then application development is accelerated, but manipulation efficacy and ease of use are reduced
Solution Approach 1:
The patent utilizes parameter changes in guide RNA sequences (spacer length, composition, structural elements) and effector protein domains to systematically tune manipulation efficacy for different applications. By adjusting these parameters, the same core system can be optimized for high-throughput screening, precise base editing, or large-scale genome engineering without redesigning the entire system, thereby maintaining ease of use while increasing productivity.
3Adaptability or versatility
If canonical DNA and RNA endonuclease activities are used, then nucleic acid cleavage is achieved, but diverse manipulation mechanisms are limited
Solution Approach 1:
The patent creates composite effector proteins by combining Type III-E CRISPR-Cas domains with additional functional domains (DEAL for DNA endonuclease, RAMP for RNA processing, CHAT for protease activity). These composite proteins integrate multiple activities within a single molecular complex, enabling diverse manipulation mechanisms (cleavage, insertion, deletion, editing) while maintaining reliable target-specific recognition through the guide RNA-directed binding mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise and efficient manipulation of nucleic acids, including cleavage and modification, with applications in nucleic acid detection, editing, and treatment of conditions like cancer and infectious diseases, leveraging diverse mechanisms beyond canonical DNA and RNA endonuclease activities.
Implementation Method 1
the effector protein is capable of binding to the Type III-E RNA guide and of targeting the target nucleic acid sequence complementary to the spacer sequence
Implementation Method 2
a spacer sequence capable of hybridizing to a target nucleic acid
Implementation Method 3
capable of cleavage, insertion, and deletion events
Data Source
AI summary
The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.